TOT BIOPHARM International Co. Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009 and is headquartered in Suzhou, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company